Drug interaction study between bupropion and ticlopidine in male CF-1 mice

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 3, 2011, Pages 447-451

  Molnari, Jillissa Christine ^a   Hassan, Hazem EmadEldin ^b,c   Moeller, Bryant Michael ^a   Myers, Alan Lewis ^a  

^a DRAKE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c Helwan   (Egypt)

Author keywords

Bupropion; Cytochrome P450 2B6; Drug drug interaction; Pharmacokinetics; Ticlopidine

Indexed keywords

AMFEBUTAMONE; RADAFAXINE; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION;

ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BRAIN; BUPROPION; DRUG INTERACTIONS; DRUG TOXICITY; ENZYME INHIBITORS; HYDROXYLATION; MALE; MICE; MICE, INBRED STRAINS; OXIDOREDUCTASES, N-DEMETHYLATING; TICLOPIDINE;

EID: 79952339950     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.447     Document Type: Article

References (41)

1. Hesse L. M., Venkatakrishnan K., Court M. H., von Moltke L. L., Duan S. X., Shader R. I., Greenblatt D. J., Drug Metab. Dispos., 28, 1176-1183 (2000).
2. Dwoskin L. P., Rauhut A. S., King-Pospisil K. A., Bardo M. T., CNS Drug Rev., 12, 178-207 (2006).
3. Goodnick P. J., Psychopharmacol. Bull., 27, 513-519 (1991).
4. Johnston A. J., Ascher J., Leadbetter R., Schmith V. D., Patel D. K., Durcan M., Bentley B., Drugs, 62 (Suppl. 2), 11-24 (2002).
5. Posner J., Bye A., Dean K., Peck A. W., Whiteman P. D., Eur. J. Clin. Pharmacol., 29, 97-103 (1985).
6. Welch R. M., Lai A. A., Schroeder D. H., Xenobiotica, 17, 287-298 (1987).
7. Suckow R. F., Smith T. M., Perumal A. S., Cooper T. B., Drug Metab. Dispos., 14, 692-697 (1986).
8. Faucette S. R., Hawke R. L., Lecluyse E. L., Shord S. S., Yan B., Laethem R. M., Lindley C. M., Drug Metab. Dispos., 28, 1222-1230 (2000).
9. Bogaards J. J., Bertrand M., Jackson P., Oudshoorn M. J., Weaver R. J., van Bladeren P. J., Walther B., Xenobiotica, 30, 1131-1152 (2000).
10. Beyens M. N., Guy C., Mounier G., Laporte S., Ollagnier M., Drug Saf., 31, 1017-1026 (2008).
11. Chapman S. C., Jamrozik K., Med. J. Aust., 176, 134 (2002).
12. Davidson J., J. Clin. Psychiatry, 50, 256-261 (1989).
13. Golden R. N., James S. P., Sherer M. A., Rudorfer M. V., Sack D. A., Potter W. Z., Am. J. Psychiatry, 142, 1459-1462 (1985).
14. Wooltorton E., CMAJ, 166, 68 (2002).
15. Shepherd G., Pharmacotherapy, 25, 1378-1382 (2005).
16. Hill S., Sikand H., Lee J., Prim. Care Companion J. Clin. Psychiatry, 9, 67-69 (2007).
17. Welsh C. J., Doyon S., N. Engl. J. Med., 347, 951 (2002).
18. Walsky R. L., Astuccio A. V., Obach R. S., J. Clin. Pharmacol., 46, 1426-1438 (2006).
19. Walsky R. L., Obach R. S., Drug Metab. Dispos., 35, 2053-2059 (2007).
20. Turpeinen M., Tolonen A., Uusitalo J., Jalonen J., Pelkonen O., Laine K., Clin. Pharmacol. Ther., 77, 553-559 (2005).
21. Nishiya Y., Hagihara K., Ito T., Tajima M., Miura S., Kurihara A., Farid N. A., Ikeda T., Drug Metab. Dispos., 37, 589-593 (2009).
22. Wang J. S., DeVane C. L., Gibson B. B., Donovan J. L., Markowitz J. S., Zhu H. J., Psychopharmacology (Berl.), 183, 490-499 (2006).
23. Loboz K. K., Gross A. S., Ray J., McLachlan A. J., J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci., 823, 115-121 (2005).
24. Bailer A. J., J. Pharmacokinet. Biopharm., 16, 303-309 (1988).
25. Raschetti R., Morgutti M., Menniti-Ippolito F., Belisari A., Rossignoli A., Longhini P., La Guidara C., Eur. J. Clin. Pharmacol., 54, 959-963 (1999).
26. Turpeinen M., Nieminen R., Juntunen T., Taavitsainen P., Raunio H., Pelkonen O., Drug Metab. Dispos., 32, 626-631 (2004).
27. DeVane C. L., Liston H. L., Markowitz J. S., Clin. Pharmacokinet., 41, 1247-1266 (2002).
28. Murdoch D., McTavish D., Drugs, 44, 604-624 (1992).
29. Bodkin J. A., Lasser R. A., Wines J. D. Jr., Gardner D. M., Baldessarini R. J., J. Clin. Psychiatry, 58, 137-145 (1997).
30. DeBattista C., J. Psychopharmacol., 20, 11-18 (2006).
31. DeBattista C., Solvason H. B., Poirier J., Kendrick E., Schatzberg A. F., J. Clin. Psychopharmacol., 23, 27-30 (2003).
32. Fredman S. J., Fava M., Kienke A. S., White C. N., Nierenberg A. A., Rosenbaum J. F., J. Clin. Psychiatry, 61, 403-408 (2000).
33. Marshall R. D., Johannet C. M., Collins P. Y., Smith H., Kahn D. A., Douglas C. J., J. Psychopharmacol., 9, 284-286 (1995).
34. Mischoulon D., Nierenberg A. A., Kizilbash L., Rosenbaum J. F., Fava M., Can. J. Psychiatry, 45, 476-481 (2000).
35. Nelson J. C., J. Clin. Psychiatry, 59 (Suppl. 5), 65-68; discussion 69 (1998).
36. Zisook S., Rush A. J., Haight B. R., Clines D. C., Rockett C. B., Biol. Psychiatry, 59, 203-210 (2006).
37. Ashton A. K., Rosen R. C., J. Clin. Psychiatry, 59, 112-115 (1998).
38. Labbate L. A., Grimes J. B., Hines A., Pollack M. H., Ann. Clin. Psychiatry, 9, 241-245 (1997).
39. Rudkin L., Taylor M. J., Hawton K., Cochrane Database Syst. Rev., CD003382 (2004).
40. Taylor M. J., Rudkin L., Hawton K., J. Affect. Disord., 88, 241-254 (2005).
41. Woodrum S. T., Brown C. S., Ann. Pharmacother., 32, 1209-1215 (1998).